Previous Close | 14.00 |
Open | 13.70 |
Bid | 14.30 x 150000 |
Ask | 14.80 x 150000 |
Day's Range | 13.70 - 13.70 |
52 Week Range | 10.80 - 18.30 |
Volume | |
Avg. Volume | 8 |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | May 06, 2024 - May 10, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
FT. MYERS, Fla., March 27, 2024--NeoGenomics will present data at AACR, showing its commitment to advancing cancer patient care through innovative research & development initiatives.
NeoGenomics (NEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The consensus price target hints at a 43.3% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.